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Abstract
Background: Dendritic cells (DC) are the most potent antigen presenting cells (APC) of the immune system. Prostaglandin
E2, cyclic AMP, and protein kinase A (PKA) have all been shown to regulate DC maturation and activity. In other cells, the
ability of these molecules to convey their signals has been shown to be dependent on A-kinase anchoring proteins (AKAPs).
Here we present evidence for the existence and functional importance of AKAPs in human DC.
Methodology/Principal Findings: Using immunofluorescence and/or western analyses we identify AKAP79, AKAP149,
AKAP95, AKAP LBC and Ezrin. We also demonstrate by western analysis that expression of AKAP79, AKAP149 and RII are
upregulated with DC differentiation and maturation. We establish the functional importance of PKA anchoring in multiple
aspects of DC biology using the anchoring inhibitor peptides Ht31 and AKAP-IS. Incubation of protein or peptide antigen
loaded DC with Ht31 or AKAP-IS results in a 30–50% decrease in antigen presentation as measured by IFN-c production
from antigen specific CD4
+ T cells. Incubation of LPS treated DC with Ht31 results in 80% inhibition of TNF-a and IL-10
production. Ht31 slightly decreases the expression of CD18 and CD11a and CD11b, slightly increases the basal expression of
CD83, dramatically decreases the LPS stimulated expression of CD40, CD80 and CD83, and significantly increases the
expression of the chemokine receptor CCR7.
Conclusions: These experiments represent the first evidence for the functional importance of PKA anchoring in multiple
aspects of DC biology.
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Introduction
Dendritic cells (DC) are professional antigen presenting cells
(APC) capable of stimulating resting T cells to generate an antigen
specific primary immune response. DC capture, process and
present antigen bound to MHC for recognition by and subsequent
activation of T cells [1].
Recent studies indicate that prostaglandin E2 (PGE2)i s
produced by DC upon maturation [2]. PGE2 can stimulate
production of the small molecule second messenger cyclic AMP
(cAMP). In murine DC, cAMP can inhibit antigen presentation,
MHC class II expression and tumor necrosis factor-a (TNF-a)
production, and can increase interleukin-10 (IL-10) production,
resulting in overall suppression of the immune response [3]. In
contrast to the murine system, cyclic AMP elevating agents have
been shown to stimulate human DC inducing their activation and
migration [4,5]. One mediator of cAMP action is protein kinase A
(PKA). PKA is a serine/threonine protein kinase that is involved in
promoting DC maturation and inhibiting IL-12 and TNF-a
production [6,7]. PKA is a holoenzyme comprised of a dimer of
regulatory subunits each of which binds one catalytic subunit.
There are four isoforms of regulatory subunits (RIa,R I b and
RIIa, RIIb), and three isoforms of catalytic subunits (Ca,C b,C c).
The catalytic subunits are inactive when bound to the regulatory
subunits and are activated by cAMP binding to the regulatory
subunits inducing the release and activation of the catalytic
subunits [8].
It is now widely accepted that PKA actions are regulated
spatially and temporally through interactions of the regulatory
subunits with A-kinase anchoring proteins (AKAPs). AKAPs are a
family of proteins that mediate the effects of cAMP by targeting
two effectors of cAMP, PKA and the exchange protein directly
activated by cAMP (Epac) [9,10]. Disruption of PKA binding to
AKAPs in mouse and human T cells blocks the ability of cAMP to
inhibit T cell activation [11,12]. However, the involvement or
even the presence of AKAPs in dendritic cells has not yet been
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4807reported. Here we present the novel findings that AKAPs are
present in dendritic cells and that AKAP expression is differen-
tially induced upon maturation from a monocyte to a mature DC.
Additionally, we demonstrate that type II PKA binding to AKAPs
is necessary for optimal antigen presentation and activation of
CD4
+ T cells, for TNF-a and IL-10 production, and for cell
surface expression of costimulatory molecules, integrins, and the
chemokine receptor CCR7.
Results
AKAPs are expressed in dendritic cells
The ability of a dendritic cell to process and present antigen and
to stimulate T cells varies with maturation state [13]. Thus, we
examined the expression of AKAPs in CD14 purified monocytes
(MO), immature dendritic cells (iDC; 5 days with GM-CSF and
IL-4) and mature dendritic cells (mDC; two additional days with
LPS) by western analyses. As depicted in Figure 1, Ezrin,
AKAP79, AKAP149, AKAP95, and AKAP LBC were detected.
Well characterized antibodies for Ezrin, AKAP79, AKAP149,
AKAP95, RIIa,R I a, and GAPDH recognize a single band of the
expected molecular weight as indicated. AKAP-Lbc antibody
recognized several bands of lower molecular weights, which may
be break down products of the full length protein. Figure 1A is one
representative set of westerns. Quantitation of five sets of westerns
for Ezrin, AKAP79, AKAP149, AKAP95, RIIa,R I a, and
GAPDH illustrated that the expression of AKAP149 and AKAP79
was upregulated 10 and 100 fold, respectively, as the monocytes
became immature DC (iDC) and increased again 1.9 and 1.5 fold
as the immature DC fully matured (mDC) (Figure 1C). AKAP 95
and Ezrin were detected in relatively equal amounts at each stage
as any differences are not statistically significant. The amount of
the RIIa regulatory subunit of PKA expressed increased 1.8 fold
as the monocyte became an immature DC, however, the
additional increase in RIIa signal between the immature and
mature DC was not statistically significant. The RIa regulatory
subunit of PKA was detected at equal levels in each cell
population. GADPH was used as a loading control and shows
no significant changes in expression among the three cell
populations. AKAP-Lbc was detected in iDC and mDC with a
significant (3 fold) upregulation of AKAP-Lbc between iDC and
mDC (Figure 1B). Three sets of AKAP-Lbc westerns were
quantitated. AKAP-Lbc protein was only detected when cells
were lysed in Lbc lysis buffer (see materials and methods). Protein
quality from monocytes was not acceptable using this method of
cell lysis; therefore we make no claims about the presence of
AKAP-Lbc in monocytes. These data identify specific AKAPs in
DC and further illustrate that the expression of some AKAP and
PKA proteins are upregulated with DC maturation.
Subcellular localization of AKAPs
The ability of AKAPs to coordinate cAMP signaling events is
through spatio-temporal localization of signaling molecules bound
to the AKAP. Localization is mediated by unique targeting
domains within each AKAP. Using immunofluorescent confocal
microscopy we illustrate that AKAP79, AKAP149, AKAP95, and
Figure 1. Identification of AKAPs in dendritic cells by western
analysis. Monocytes were isolated from PBMC by negative isolation of
CD14
+ cells (Mo), plated in culture for 5 days with GM-CSF and IL-4
(immature DC; iDC) or plated for five days with GM-CSF and IL-4 and an
additional two days with LPS (mature DC; mDC). See Materials and
Methods for details. A) One representative set of westerns in which
10 mg total protein was loaded in each lane. Membranes were probed
with monoclonal antibodies to AKAP149, AKAP95, AKAP79, RIIa,R I a,
and GAPDH, goat-anti-mouse HRP conjugated secondary and chemi-
luminescence detection. B) One representative western in which 10 mg
of total protein was loaded in each lane. The membrane was probed
with a rabbit polyclonal antibody to AKAP-Lbc (generous gift of Dr.
Diviani), goat-anti-rabbit HRP conjugated secondary and chemilumi-
nescence detection. C) Quantitation of five westerns using NIH image
quantitation software. One way ANOVA for three correlated samples
yielded significance with p=0.0004 for AKAP149; p,0.0001 for AKAP79,
and p=0.003 for RIIa. A Tukey HSD test confirmed statistical
significance between Mo and iDC (a) and between iDC and mDC (b)
p,0.05. Quantitation of three westerns and student ttest for AKAP-Lbc
yielded statistical significance (c) p=0.005.
doi:10.1371/journal.pone.0004807.g001
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Antibody to HLA-DR was used to delineate the cell (Figure 2
panels B, C, K, and L). AKAP79 was detected in the membrane
(Figure 2; panels A, C, D, and F). In some cells AKAP79 staining
overlaps strikingly with HLA-DR staining (panels A–C, arrows);
while in other cells staining for AKAP79 and HLA-DR appears to
be exclusive (panels A–C, arrowheads). As expected, AKAP79
staining also overlaps with RII staining (Figure 2; panels D–F).
AKAP149 was detected predominantly in the mitochondria with
some nuclear staining (Figure 2; panels G–I). Mitochondrial
staining was confirmed by overlapping signals with the mitochon-
drial marker mitotracker. Staining for AKAP95 reveals a
characteristic pattern of nuclear expression, HLA-DR was used
to provide a cellular outline and hoescht stain was used to confirm
nuclear localization (Figure 2; panels J–L). Ezrin staining is
strongest in the membrane ruffles and leading edge of the cells
(Figure 2; panel M). A zoom of the outlined region in panel M is
used to illustrate overlapping Ezrin and RII staining in the
membrane (Figure 2; panels P–R). Secondary antibody staining
for Texas Red conjugates is minimal (Figure 2; panel N).
Secondary antibody staining for FITC conjugates is significant
but different than most of the primary staining of interest (Figure 2;
panel O). The majority of the FITC secondary staining was in the
nucleus, thus this conjugate was not used for AKAP95
visualization. The pattern of staining in immature DC was found
to be similar to the mature DC (data not shown) suggesting that
the changes present in protein expression (Figure 1) are likely in
the amount of protein being produced rather than changes in
localization.
Disrupting PKA anchoring inhibits antigen presentation
To determine if AKAPs have a function in regulating antigen
presentation, we disrupted the PKA/AKAP interaction using the
Ht31anchoring inhibitor and Ht31p control peptides. The
anchoring inhibitor Ht31 is a peptide that forms an amphipathic
helix which binds to RII preventing its binding to AKAPs. The
control peptide, Ht31p, incorporates a proline mutation which
kinks the helix, thwarting its ability to bind and disrupt PKA
anchoring. Immature DC (day 5) were treated with Ht31 or the
Ht31p control peptide and loaded with either CFP10 protein or
peptide antigen at the indicated concentrations. CFP10 is an
immunodominant Tuberculosis antigen used here as a tool to
observe antigen presentation and T cell activation. D454 E12
clonal CD4
+ T cells specific for CFP10 were then added to the
DC. T cell activation was measured by ELISPOT analysis of IFN-
c production (see material and methods). The ability of the DC to
present antigen and activate the T cells was significantly reduced
in the presence of the Ht31 peptide. Figure 3A is one
representative ELISPOT of an antigen titration experiment. The
experiment was repeated at least three times using DC from
different matched and unmatched donors. The data were
normalized and averaged for graphical presentation in Figure 3B.
IFN-c production (spot forming units) was reduced an average of
33% when comparing Ht31 treated DC to untreated DC and 28%
when comparing Ht31 treated DC to Ht31p treated DC, in
CFP10 protein loaded cells. When CFP10 peptide was used as
antigen, IFNc production was reduced 50% in Ht31 treated DC
versus untreated DC. The reduction was 39% when comparing
Ht31 treated DC to Ht31p treated DC (Figure 3C). These data
suggest that PKA anchoring is required for optimal antigen
presentation and T cell activation.
To confirm that Ht31 is disrupting PKA anchoring in the
dendritic cells and not in the T cells, two different experiments are
presented. Ht31 or Ht31p were added to day 5 immature DC with
0.03 mg/ml CFP10 protein antigen. The cells were incubated for
1 hour at 37uC and rinsed to remove the peptides. Fresh media
and the D454 E12 clonal T cells were then added and IFN-c
production was assayed by ELISPOT. As presented in Figure 3D,
Ht31 added to the DC inhibited the ability of the DC to activate
the T cells. IFN-c production from the T cells in Ht31 treated DC
was reduced 43% compared to untreated control DC and Ht31p
treated DC, suggesting that Ht31 is disrupting PKA anchoring
and antigen presentation within the DC. In Figure 3E, D454 E12
clonal CD4
+ T cells were treated with 100 mM Ht31 or Ht31p for
1 hour at 37uC, the T cells were rinsed and added to antigen
loaded DC and IFN-c production was assayed by ELISPOT.
Consistent with figure 3b, the first set of bars illustrate, IFN-c
production is inhibited in Ht31 treated DC. However, the second
set of bars reveals that when the T cells are treated with Ht31,
IFN-c production is not inhibited. These data provide evidence
that the inhibition of IFN-c production presented in these
experiments is the result of Ht31 disrupting anchoring within
the DC.
To illustrate that inhibition of T cell activation is not specific to
T cell clones, we performed a mixed lymphocyte reaction (MLR).
In Figure 3F, day 5 DC matured from CD14
+ monocytes were
incubated without or with 100 mM Ht31or Ht31p and PBMC for
3 days. IFN-c production was measured by ELISPOT and
presented as normalized and averaged cytokine activity. The data
illustrate that Ht31 treatment of the DC significantly inhibits T cell
activation 40–56% depending on the number of PBMC used (40%
using 125,000 PBMC, 56% using 62,500 PBMC). The control
Ht31p peptide does not inhibit T cell activation. These data
confirm that the ability of Ht31 to disrupt antigen presentation
and T cell activation is not specific to T cell clones and can be
illustrated in peripheral blood T cells. Collectively these data
demonstrate that PKA anchoring is important in the regulation of
antigen presentation and T cell activation by DC.
To examine the ability of Ht31 to reverse the effects of known
PKA activators we performed ELISPOT analyses in the presence
of forskolin and PGE2. In agreement with published studies using
human DC, forskolin (10 mM) and PGE2 (1 mM) increased antigen
presentation (Figure 4, green and purple bars, respectively). Ht31
reversed the effects of forskolin and PGE2 (Figure 4, green-red
hatched bars and purple-red hatched bars), respectively while
Ht31pro did not (Figure 4, green-blue hatched and purple-blue
hatched bars, respectively). These results support the hypothesis
that Ht31 inhibits antigen presentation by interfering with PKA
signaling.
We next examined the ability of DC to secrete the immuno-
suppressive cytokine IL-10 in the presence of Ht31 or Ht31p when
stimulated with Zymosan or LPS. Day 5 DC were incubated with
30 mg/ml Zymosan or 10 ng/ml LPS overnight and supernatants
were used in ELISAs. The data illustrate that 100 mM Ht31
inhibited the secretion of IL-10 from Zymosan treated cells by
35% and LPS treated cells by 65% (Figure 5, red bars). The
control peptide Ht31p has no significant effect on cytokine
secretion. These data suggest that PKA signaling is important for
IL10 secretion.
The robust inhibition IL-10 secretion prompted examination of
cell viability in the presence of Ht31 and Ht31p. Day 5 DC were
treated with Ht31 or Ht31p overnight and stained with annexin
V/PI. An average of three experiments illustrates that less than
20% of DC exhibited annexin V/PI positive staining (Figure 6,
black bar). Incubation with Ht31 reduced the annexin V/PI
staining to 6% (Figure 6, red bar), while Ht31p treated cells
averaged 10.5% annexin V/PI positive staining (Figure 6, blue
bar). These differences were found to be statistically significant
AKAPs in Dendritic Cells
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fact be preventing cell death.
To dissect which PKA isoforms were contributing to the
inhibition of antigen presentation we performed ELISPOT
experiments using the RII selective inhibitor AKAP-IS and the
RI selective inhibitor RIAD along with their control peptides SCR
and RSCR [14,15]. The poly-arginine containing peptides were
added to DC at the indicated concentrations, 0.1 mg/ml CFP10
protein antigen and D454 E12 CD4
+ clonal T cells were added as
in figure 3a. Interferon-c production from three experiments was
Figure 3. Anchored PKA is required for antigen presentation as assayed by IFN-c ELISPOT. A) One representative ELISPOT. Day 5
dendritic cells (iDC) were incubated without (Unt, black bars) or with Ht31 (red bars) or Ht31p (blue bars), and the indicated concentration of CFP10
protein (B) or CFP10 peptide antigen (C) for 1 hr at 37uC. Antigen specific CD4
+ clonal T cells were added and IFN-c production was assayed after
16 hours by ELISPOT. D) Allogeneic day 5 dendritic cells (iDC) were incubated without (Unt, black bars) or with Ht31 (red bars) or Ht31p (blue bars) for
1h ra t3 7 uC, 5% CO2. The cells were collected, rinsed and replated. Then 0.03 mg/ml of protein antigen (CFP10) was added for 1 hr at 37uC, 5% CO2,
and antigen specific CD4
+ clonal T cells were added. IFN-c production was assayed after 16 hours by ELISPOT. E) First set of three bars, experiment is
conducted as in (B). Second set of three bars, antigen specific CD4
+ clonal T cells were incubated without (Unt, black bars) or with Ht31 (red bars) or
Ht31p (blue bars) for 1 hr at 37uC, rinsed, and added to allogeneic day 5 DC preloaded with CFP10 protein antigen (0.03 mg/ml). IFN-c production was
assayed after 16 hours by ELISPOT. The data presented are an average of three independent experiments with values (number of spots counted)
normalized to the response at 0.03 mg/ml CFP10 protein (B), 0.03 mg/ml CFP10 peptide (C). F) MLR, CD14
+ monocytes were matured and 10,000 DC
were plated with 125,000 or 62,500 PBMC as indicated, without (Unt, black bars) or with 100 mM Ht31 (red bars) or Ht31p (blue bars). In all figures
error bars represent S.E.M. (B) Two factor ANOVA with repeated Measures on Both Factors was conducted on the un-normalized values (actual count
of number of cells making IFN-c,P ,0.05). (C, D, E, F) A student TTEST yielded significance with a P,0.05 (*) or P,0.01 (**).
doi:10.1371/journal.pone.0004807.g003
Figure 2. Immunofluorescence of AKAPs in dendritic cells. Monocytes derived from adherence to plastic were plated onto poly-l-lysine
coated glass coverslips. The cells were incubated for 30 minutes with mitotracker (panels H, I), and/or fixed, permeabilized, and stained with
monoclonal antibodies to AKAP79 (panels A, C, D, F), AKAP149 (panels G, I), AKAP95 (panels J, L), HLA-DR (panels B, C, K, L), Ezrin (panels M, P), RIIb
(panels, E, F, Q, R). Hoescht (panel K, L) was added with secondary antibody conjugates. Panels P-R are 2 fold zoom of the boxed area of panel M.
Scale bar=25 mm.
doi:10.1371/journal.pone.0004807.g002
AKAPs in Dendritic Cells
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presentation is inhibited approximately 50% by 25 mM AKAP IS.
Inhibition increases to about 75% with 100 mM AKAP IS. In
contrast, RIAD does not significantly inhibit antigen presentation
at 25 mM and inhibits about 25% at 100 mM (Figure 7B). Studies
in T cells suggest that RIAD should disrupt type I PKA anchoring
at concentrations less than 10 mM [15]. Thus these data suggest
that antigen presentation is more dependent on signaling via the
RII isoforms of PKA.
To determine if the suboptimal stimulation of T cells by DC was
due to regulation of costimulatory molecules or integrins, the
expression of CD18, CD11a, CD11b, CD11c, CD40, CD80,
CD83, CD49d, CD86, and HLA-DR on DC were examined. Day
5 DC were incubated without or with Ht31 or Ht31p, and without
or with Ht31 or Ht31p in the presence of LPS for 48 hours at
37uC, 5% CO2. In figure 8 columns A and C illustrate one
representative set of FACS analysis for each molecule. In A,
untreated cells are represented by the black trace, Ht31 treated
cells are indicated by the red trace, and Ht31p treated cells are
shown as the blue trace. In C, LPS treated cells are illustrated by
the orange trace, LPS with Ht31 are red and LPS with Ht31p are
Figure 4. Ht31 blocks the ability of PKA activators to stimulate
antigen presentation and T cell activation. Day 5 DC were
incubated in the absence (black bar) or presence of 10 mM forskolin
(green bars) or 1 mM PGE2 (purple bars) and in the absence or presence
of 100 mM Ht31 (red and red hatched bars) or 100 mM Ht31p (blue and
blue hatched bars). CFP10 protein antigen (0.03 mg/ml) was added and
after 1 hr incubation at 37uC, 5% CO2, antigen specific CD4
+ clonal T
cells were added. IFN-c production was assayed by ELISPOT after 16 hr
at 37uC, 5% CO2. Six experiments were normalized and averaged. Error
bars are S.E.M. Student TTEST reveals significance P,0.05(*).
doi:10.1371/journal.pone.0004807.g004
Figure 5. Ht31 inhibits secretion of IL-10. Day 5 DC were
incubated with 30 mg/ml Zymosan or 10 ng/ml LPS, without (Unt,
black bars) or with 100 mM Ht31 (red bars) or Ht31p (blue bars) for
24 hours at 37uC, 5% CO2. Supernatants were collected and used in IL-
10 ELISA (R&D Systems). Three experiments were normalized and
averaged. Error bars are S.E.M. Student TTEST reveals significance,
P,0.05(*) or P,0.005(**).
doi:10.1371/journal.pone.0004807.g005
Figure 6. Ht31 is not inducing cell death. Day 5 DC were incubated
without (Unt, black bars) or with 100 mM Ht31 (red bars) or Ht31p (blue
bars) for 48 hours, collected, stained with annexin V and propidium
iodide and analyzed by FACS. Percent annexin V/PI positive events from
three different donors were averaged. Error bars are S.E.M. Student ttest
reveals significance, P,0.05(*).
doi:10.1371/journal.pone.0004807.g006
Figure 7. Inhibition of antigen stimulation is mediated by
signaling from type II PKA. Allogeneic day 5 dendritic cells (iDC)
were incubated without (Unt, black bars) or with A) the indicated
concentrations of type II anchoring inhibitor (IS, red bars) or the control
(SCR, blue bars), or B) the indicated concentrations of type I anchoring
inhibitor (RIAD, red bars) or the control (RSCR, blue bars) for 1 hr at
37uC, 5% CO2. The cells were collected, rinsed and replated. Then
0.1 mg/ml of protein antigen (CFP10) was added for 1 hr at 37uC, 5%
CO2, and antigen specific CD4
+ clonal T cells were added. IFN-c
production was assayed after 16 hours by ELISPOT. Data are an average
of three donors. Error bars are S.E.M. Student ttest reveals significance,
P,0.05(*).
doi:10.1371/journal.pone.0004807.g007
AKAPs in Dendritic Cells
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percent inhibition (B) or average percent increase (D) from 8 or 5
donors, respectively. The data illustrate that Ht31 inhibits the cell
surface expression of CD18 by nearly 30% and CD11a by 10%
(Figure 8 A and B). Expression of CD18 and CD11a in the
presence of LPS was not significantly altered (Figure S1 A and B).
Expression of CD83 was consistently increased in cells treated with
Ht31 (Figure 8 A and B). In LPS treated cells, CD40, CD80 and
CD83 expression increased appreciably as expected, but this
increase was significantly inhibited by Ht31 and not Ht31p
(Figure 8 C and D). Expression of CD11b was increased by Ht31
but not significantly, and no significant changes were found in
CD11b expression in the presence of LPS (Figure S1 A–D).
Expression of CD49d was significantly inhibited by Ht31, but the
same level of inhibition was consistently detected in the presence of
Ht31p (Figure S1 E and F). No significant changes were detected
in the expression of CD11c, CD86 or HLADR in the presence of
Ht31 or Ht31p with or without LPS (Figure S1 E and F). These
data are consistent with the idea that PKA anchoring is required
for proper cell surface expression of adhesion and costimulatory
molecules on immature DC and during DC maturation.
While the experiments presented to this point fit a model in
which PKA activation stimulates DC and inhibiting PKA signaling
by disrupting anchoring blocks this stimulatory signal, two sets of
experiments resulted in data that does not fit with this model.
TNF-a secretion was measured by ELISA from day 5 DC
stimulated with LPS. In agreement with published studies,
incubating cells with 1 mM PGE2 inhibits TNF- a production
from DC an average of 82% (Figure 9A, purple bar). Interestingly,
incubating DC with Ht31 (100 mM) also inhibited the secretion of
TNF-a from LPS stimulated DC by an average of 74% (Figure 9A,
red bars). The control peptide Ht31p has no significant effect on
TNF-a secretion (Figure 9A, blue bars). Incubation with both
Ht31 and PGE2 increase the average inhibition to nearly 95%
(Figure 9A, red and purple hatched bars) while incubation with
Ht31p again had no effect on the inhibition mediated by PGE2
(Figure 9A, blue and purple hatched bars). To confirm that the
inhibition of TNF-a production was not on contaminating T cells
instead of the DC, we matured DC from CD14
+ negatively
selected monocytes (98% pure as determined by FACS),
stimulated with LPS in the presence or absence of Ht31 or
Ht31p and assayed TNF-a secretion. The results obtained from
Figure 8. Ht31 inhibits cell surface expression of CD18, CD40, CD80 and CD83. Day 5 DC were incubated without or with 10 ng/ml LPS and
100 mM Ht31 or Ht31p for 48 hours. Cells were collected, blocked, and stained for cell surface expression using conjugated antibodies, see materials
and methods. FACS analysis was performed on a LSRII using FacsDiva software. A) One representative histogram showing untreated cells (black
trace), Ht31 treated cells (red trace), and Ht31p treated cells (blue trace). B) Graphical representation of percent inhibition of mean fluorescent
intensities compared to untreated samples, data from eight donors was normalized and averaged. C) One representative histogram showing
untreated cells (black trace), LPS treated cells (orange trace), LPS+Ht31 (red trace), and LPS+Ht31p (blue trace). D) Graphical representation of percent
increase in mean fluorescent intensity compared to untreated cells, data from five donors was normalized and averaged. Error bars are S.E.M. Student
ttest yielded statistical significance as indicated, P,0.05 (*), P,0.1 (**).
doi:10.1371/journal.pone.0004807.g008
AKAPs in Dendritic Cells
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derived DC (data not shown). Furthermore, Ht31 had no effect on
TNF-a secretion from unstimulated cells (data not shown).
In addition, the expression of the chemokine receptor CCR7
was enhanced in the presence of PGE2 and Ht31. Day 5 DC were
incubated with 1 mM PGE2 in the absence or presence of 100 mM
Ht31 or 100 mM Ht31p. Cells were collected, stained for CCR7
expression and analyzed by FACS. The data presented in figure 9b
illustrate an increase of CCR7 expression in a population of cells.
The numbers represent the % events in the boxed area. The
average results from three independent donors were normalized to
untreated and presented as percent increase in mean fluorescence
intensity. Ht31 increases CCR7 expression by 60% (Figure 9c, red
bars), PGE2 increases CCR7 expression by 200% (Figure 9c,
purple bars), and PGE2 with Ht31 increases CCR7 expression by
an additional 150% (350% increase over untreated) (Figure 9c, red
and purple hatched bars). The Ht31p peptide does not increase
CCR7 expression on its own (Figure 9c, blue bars) or with PGE2
(Figure 9c, purple and blue hatched bars). The effects of PGE2 on
CCR7 expression have been correlated with increased migratory
capacity of DC [2], suggesting that Ht31 may also be increasing
the migratory capacity of DC.
Discussion
The data presented here portray the first evidence for
expression of AKAPs in dendritic cells and illustrate a significant
role for anchored PKA in regulating several aspects of DC biology.
Using western analyses we identified five AKAPs: AKAP149,
AKAP95 and AKAP79, Ezrin, and AKAP-Lbc. We have also
illustrated an increase in expression of AKAP149, AKAP79 and
AKAP-Lbc with DC maturation. The anchoring inhibitor
peptides Ht31, IS and RIAD were utilized to provide functional
evidence for the importance of anchored PKA activity in DC.
Ht31 peptide has been previously used to demonstrate the
importance of PKA anchoring in T cells, cardiac cells and
neuronal cells [11,12,16,17]. IS and RIAD have been utilized to
demonstrate isoform specific responses in neuronal and T cell
signaling [14,15]. Our data suggest that anchored type II PKA
regulates the ability of a DC to present antigen and activate a T
cell. Anchored PKA also regulates secretion of both pro-
inflammatory and immunosuppressive cytokines, and regulates
the cell surface expression of costimulatory molecules, integrins
and the chemokine receptor CCR7.
Interpretation of these data requires some understanding of the
multiple roles of PKA in regulating DC function and subsequent
immune responses. PKA can be activated by cell permeable
analogs of cAMP, by the adenylyl cyclase activator, forskolin, by
prostaglandins and other G-protein coupled receptor agonists and
by toxins [10]. Activation of PKA by cell permeable analogs of
cAMP, forskolin, cholera toxin and lymphotoxin has been shown
to activate DC, as characterized by increases in cell surface
expression of CD80, CD83, CD86 and HLA-DR molecules, and
the enhanced ability to present alloantigen in an MLR leading to
increased T cell proliferation [7]. In addition, PGE2 has been
shown to increase CCR7 expression and promote DC migration
[5]. In contrast, much evidence also exists supporting the notion
Figure 9. Ht31 inhibits TNF-a production and CCR7 expression.
A) Day 5 DC were incubated with 10 ng/ml LPS without (Unt, black
bars) or with 100 mM Ht31 (red bars) or Ht31p (blue bars) and 1 mM
PGE2 without (purple bars) or with 100 mM Ht31 (purple and red
hatched bars) or Ht31p (purple and blue hatched bars) for 24 hours at
37uC, 5% CO2. Supernatants were collected and used in TNF-a ELISA
(Ebioscience). Three experiments were averaged. Error bars are S.E.M.
Student TTEST reveals significance, P,0.05(*). B, C) Day 5 DC were
incubated without (Unt, black bars) or with 100 mM Ht31 (red bars) or
Ht31p (blue bars) and 1 mM PGE2 without (purple bars) or with 100 mM
Ht31 (purple and red hatched bars) or Ht31p (purple and blue hatched
bars) for 48 hours at 37uC, 5% CO2. Cells were collected, blocked, and
stained for cell surface expression with anti-CCR7. FACS analysis was
performed on a LSRII using FacsDiva software. B) One representative
dot plot for each treatment. C) Three experiments normalized to
untreated and averaged. Error bars are S.E.M. Student ttest reveals
significance, P,0.05(*).
doi:10.1371/journal.pone.0004807.g009
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and T cell proliferation are also inhibited by PGE2 and cAMP
analogs [3]. Inhibition of the immune response by activated DC is
further supported by evidence that PGE2 and cAMP increase IL-
10 secretion and decrease the ability to present antigen and
stimulate T cell proliferation [18]. These effects have been
summarized by Harizi and colleagues who state that ‘‘PGE2 has
stimulatory and inhibitory effects on the activation of the DC
depending on the site of encounter. In peripheral tissues, PGE2
seems to have a stimulatory effect of DC inducing their activation
and migration [4,5]. Once the cells have migrated to lymphoid
organs, PGE2 assumes a suppressive action, inhibiting the
maturation of DC and their ability to present antigen [19]’’
[18]. Of note, however, is that of the studies referred to above,
those performed on DC of murine origin are inhibited by PKA
activators, while DC of human origin are stimulated by PKA
activators. The results presented here agree with those published
using human DC that PKA activators stimulated antigen
presentation, inhibited TNF production and stimulated CCR7
expression.
Historically, disruption of PKA anchoring with Ht31 has
mimicked the effect of the PKA inhibitors such as PKI peptide
[20,21]. These results have been interpreted to mean that 1) PKA
is being inhibited through delocalization and the subsequent
inability to be activated by localized increases in cAMP, 2)
signaling by PKA cannot be initiated due to delocalization from
nearby substrates. In agreement with this model, PKA activators
stimulated antigen presentation and the anchoring inhibitor Ht31
blocked the activation by PGE2 and forskolin. Ht31 and AKAP-IS
also inhibited antigen presentation on their own. Interestingly,
however, PGE2 and Ht31 both inhibited TNF-a production from
LPS stimulated DC and both PGE2 and Ht31 increased CCR7
expression in maturing DC. The effects of PGE2 and Ht31 were
additive, and the effects of neither PGE2 nor Ht31 were blocked
by PKA inhibitors PKI or H89 (data not shown). While at first
glance these data could suggest a PKA independent mechanism
for PGE2 and Ht31, PKA mediated signaling events that cannot
be blocked by H89 have been reported [22,23], and the PKI
peptide may be degraded in the multi-day assays presented here.
Thus it is possible that these events are PKA mediated and that
Ht31 is mimicking PGE2. Further experimentation is necessary to
explore this hypothesis.
Cyclic AMP analogs and PGE increase IL-10 production in DC
[24]. While PKA inhibitor studies have not been conducted in
DC, data in macrophages illustrate that cAMP increases IL-10
production, and incubation with the PKA inhibitor H89 blocks the
cAMP-mediated IL-10 induction [25]. From these data we suggest
that Ht31 is inhibiting PKA signaling and regulating IL-10
secretion. The exact mechanism is not known, but one study in
macrophages may suggest that cAMP regulates IL-10 secretion
through posttranscriptional mechanisms [26]. Additional studies
will have to be conducted to determine how Ht31 is inhibiting IL-
10 secretion in DC.
Anchored PKA activity was found to be important in regulating
the cell surface expression of co-stimulatory molecules CD40,
CD80 and CD83. Similar to the PGE studies referenced above,
Ht31 significantly increased expression of CD83. Furthermore,
Ht31 significantly decreased the expression of CD40, CD80, and
CD83 on LPS stimulated cells. Naı ¨ve T cells are dependent on
costimulation to become fully active. While effector T cells are not
dependent on costimulation, costimulation will lower the threshold
for activation. Thus the decrease in expression of costimulatory
molecules CD40, CD80, and CD83 may be increasing the
threshold for activation causing a decrease in antigen presentation.
Experiments illustrating a slight but significant decrease in
integrin expression may also be a lead as to the mechanism by
which Ht31 is inhibiting antigen presentation. Integrins are
noncovalently linked ab heterodimers, with the specific ab pairs
linked to unique components of the cytoskeleton and downstream
signaling pathways. Integrins regulate DC trafficking and immune
synapse formation through interactions with intracellular adhesion
molecules (ICAM) [27–29]. A significant body of literature has
accumulated on the involvement of PKA signaling, integrins and
cell motility [30]. Recent findings illustrate that the a4b1 integrin
is an AKAP [31], that a4b1 and a5b1 integrin ligation activates
PKA at the leading edge of cells [32], and that PKA regulates
crosstalk between a4b1 and avb3 integrins [33]. The distribution
of integrins on DC appears to be a developing field with much of
the focus on the b2 family [27]. However, more recent studies
illustrate that PGE2 and a5b1 integrins regulate DC migration [2].
While we could not find studies demonstrating a direct regulation
of integrins by PKA in DC, several studies have demonstrated
roles for regulation of b2 integrins by PKA in neutrophils. In
neutrophils, PKA activation inhibits adhesion and promotes
migration, while inhibition of PKA stimulates adhesion [34,35].
PKA phosphorylates L-plastin (LPL), a leukocyte specific actin
bundling protein that is associated with activation of aMb2
integrin mediated adhesion [36]. These data support the idea that
PKA is important in regulating integrin activity and actin
polarization, and therefore may be important in regulating
antigen presentation. Our studies on CD11a/CD18 (integrins
aLb2 or LFA), CD11b/CD18 (integrin aMb2, Mac-I or CR3),
and CD11c/CD18 (integrin aXb2, CR4) illustrate that Ht31
significantly inhibits the cell surface expression of CD18 (b2
integrin), and slightly inhibits the expression of the CD11a (aL)
and CD11b (aM) subunits. Further experimentation is necessary
to determine if Ht31-mediated changes in integrin expression are
responsible for inhibition of antigen presentation and if Ht31 is
regulating integrin activity.
Ht31 has been shown to disrupt the PKA/AKAP interaction of
nearly all AKAPs [37]. For each AKAP we have identified,
possible mechanisms for regulating antigen presentation can be
proposed. Since the most recent comprehensive AKAP review was
published [38], several studies have been conducted that may be
relevant to regulation of antigen presentation. As such we have
briefly reviewed aspects of each AKAP identified here and how it
may be implicated in regulating DC biology.
AKAP149 and AKAP95 both bind to the novel myc binding
protein AMY-1 [39]. AMY-1 is a stimulating factor for
differentiation in erythrocytes, and competes for PKAc binding
to the AKAP. Given that AKAP95 and AKAP149 protein
expression are regulated differentially in monocytes versus
immature and mature DC, the ability of each AKAP to interact
with AMY-1 may play a role in regulating DC maturation.
AKAP79 is associated with the b-adrenergic G-protein coupled
receptor [40,41]. This association facilitates phosphorylation of the
b-adrenergic receptor by PKA and switches signaling from Gs
coupled activation of adenylyl cyclase to Gi coupled activation of
the MAP kinase pathway [42]. Phosphorylation of the b-
adrenergic receptor by PKA also promotes recycling and
resensitization of the receptor [43]. b2-agonists inhibit IL-12
production from DC stimulated with CD40-CD40L interaction
[44], suggesting that b-adrenergic receptors are present in DC and
may be regulated by AKAP79.
In addition to binding PKA, AKAP-Lbc is a Rho-guanine
nucleotide exchange factor (GEF) [45,46]. AKAP-Lbc Rho-GEF
activity is activated via adrenergic signaling and Ga12 and
inactivated through interactions with 14-3-3 [47]. Activation of
AKAPs in Dendritic Cells
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formation of immune synapses in DC [48]. Hence the presence of
AKAP-Lbc in DC may indicate a mechanism for regulating
antigen presentation by way of influencing immune synapse
formation.
Ezrin, a member of the ezrin-radixin-moesin (ERM) family of
cytoplasmic linker proteins, has been shown to regulate T cell
activation via anchoring of PKA to lipid rafts [12]. Ezrin also
associates with clustered ICAMs and becomes phosphorylated on
serine, threonine, and tyrosine residues [49]. Precedence exists for
an ERM domain containing protein, talin, to activate integrin
signaling and clustering [50]. Thus it will be interesting to
determine if anchoring of PKA to Ezrin might be regulating
antigen presentation through integrin activation.
In this study we looked at the role of PKA anchoring in
regulating DC biology. Using the Ht31 inhibitor and Ht31p
control peptides in DC loaded with protein or peptide antigen, we
illustrate that type II PKA anchoring is necessary for optimal
antigen presentation and activation of antigen specific T cells and
activation of effector T cells in an allo response. Disruption of
PKA anchoring inhibits TNF-a and IL-10 production and
regulates the expression of co-stimulatory molecules, integrins,
and the chemokine receptor, CCR7. Thus, the presence and
functional importance of AKAPs in DC open an exciting new
avenue of research in understanding the molecular mechanisms of
antigen presentation, T cell activation and DC biology.
Materials and Methods
Cells
Human subjects protocols and consent forms were approved by
the Oregon Health & Science University Institutional Review
Board (IRB). Source leukocytes purchased from the Portland Red
Cross had Red Cross IRB approval and thus were exempt from
VA and OHSU IRB. Leukocytes obtained in house were obtained
with written consent from donors. Blood was obtained from the
Red Cross immediately after being drawn and processed to isolate
peripheral blood mononuclear cells (PBMC). 45–50 mls of source
leukocytes were diluted 1:1 with sterile PBS and layered on a Ficoll
gradient (25 mls of diluted blood: 12.5 mls Ficoll Paque-Plus
(Amersham-Pharmacia). The gradient was centrifuged for 30 min-
utes at 11006g at room temperature with the brake turned off.
The interface was collected and washed two times with RPMI
1640 (Invitrogen-Gibco-BRL). Cells were pelleted by centrifuga-
tion at 2506g for 10 minutes, resuspended in freezing media (25%
FCS, 12% DMSO, RPMI 1640) at 25–50 million per vial, frozen
at 280uC in Mr. Frosties (Nalgene) and transferred to liquid
nitrogen for long term storage. These cells represent PBMCs.
Monocytes, CD14
+ cells, (day 0) were obtained from PBMCs by
negative selection using either EasySep human monocyte
enrichment kit (Stem cell technologies) or Dynal monocyte
negative selection kit (Invitrogen) per manufacturer’s protocol.
Cells were analyzed by flow cytometry and found to be .95%
CD14
+. Immature dendritic cells (day 5 DC) were made by culture
of purified monocytes with 10 ng/ml GM-CSF and 10 ng/ml IL-
4 in RPMI 1640 with 10% human serum (a generous gift of Drs.
David and Deborah Lewinsohn) for 5 days. Mature dendritic cells
(day 7 DC) were made by culturing day 5 DC with 10 ng/ml GM-
CSF, 10 ng/ml IL-4, and 10 ng/ml LPS in RPMI 1640 with 10%
human serum for additional two days.
Western analysis
Day 5 and Day 7 DC were collected as follows: 1) non-adherent
cells in media were transferred to a conical tube at 4uC, 2) the
remaining adherent cells were incubated in cell dissociation media
(CDM, Sigma, St. Louis, MO) at 37uC for 15 min, 3) the flask was
whacked vigorously and the cells were added to the conical tube in
(1), 4) the flask was rinsed with PBS and added to (1), 5) the cells
were pelleted by centrifugation at 8006g for 15 min at 4uC. The
pellet was rinsed with PBS and lysed with boiling Laemmli sample
buffer for 5 minutes. Protein concentration was determined using
SPN-Protein assays (G-Biosciences, St. Louis, MO). Samples
(10 mg total protein) were subjected to SDS-PAGE and transferred
to PVDF membrane (Immobilon-P, Millipore). After transfer,
membranes were blocked in 5% milk TTBS for 1 hr. Primary
antibodies were incubated for 1 hr at RT in TTBS at the following
dilutions: Ezrin (1:1000) (Thermoscientific, Waltham, MA),
GAPDH (1:1000) (Imgenex, San Diego, CA) AKAP79 (1:250),
AKAP149 (1:250), AKAP95 (1:100), RI (1:500) and RII (1:1000)
(BD Biosciences, San Jose, CA). Secondary antibodies, goat anti-
rabbit and goat anti-mouse horseradish peroxidase conjugates,
were used at 1:5000 for 1 hr at RT (Santa Cruz Biotechnology).
NEN Renaissance chemiluminescence was used for detection.
AKAP-Lbc western
Frozen day 5 DC (2–3610
6) were lysed in 50 mM Tris-HCl
pH 7.5, 0.2% deoxycholate, 1% Triton-X, 150 mM NaCl for
30 minutes on ice and spun at 10,0006ga t4 uC for 10 minutes.
Laemmli sample buffer was added to the supernatant and samples
were boiled for 5 minutes at 97uC. Protein concentration was
determined using SPN-Protein assays (G-Biosciences, St. Louis,
MO). Samples were run on large 7% SDS-PAGE gels overnight
and transferred to Immobilon-P membrane. Membranes were
blocked in 5% milk-TTBS for 1 hour, incubated with anti-AKAP-
Lbc antibody (generously provided by Dr. Dario Diviani) at
1:1000 dilution, and goat-anti-rabbit HRP conjugated secondary
antibody at 1:5000 dilution (Santa Cruz biotechnology). NEN
Renaissance chemiluminescence was used for detection.
Immunofluorescence
Day 5 DC were generated by plating day 5 DC onto poly-l-
lysine (Sigma-Aldrich) coated round coverslips in a 12 well plate
and incubating in RPMI 10% human serum for 3 hours. Day 7
DC were generated by plating day 5 DC onto poly-l-lysine (Sigma-
Aldrich) coated round coverslips in a 12 well plate and incubating
in RPMI 10% human serum with GM-CSF, IL-4, and LPS
(10 ng/ml final concentrations) for two days. The DC were fixed
with 2% paraformaldehyde in PBS for 1 hr, washed with PBS and
blocked with 2% human serum, 2% goat serum and 0.5% fetal
calf serum in PBS with 0.1% saponin 15 minutes to overnight at
4uC. DC were washed 36with 1 ml of PBS+0.1% saponin and
incubated with primary antibody (1:100 dilution) in PBS+0.1%
saponin in a moist staining chamber for 1 hr. The primary
antibodies are the same as those used for westerns with the
exception of RIIb (anti-rabbit antibody, Biomol, PA), and FITC
conjugated HLA-DR (BDbiosciences). DC were again washed
36with 1 ml of PBS+0.1% saponin and incubated with secondary
antibody (donkey anti mouse or donkey anti rabbit, FITC or
TxRd, Jackson Immuno Research Laboratories, West Grove, PA)
in PBS+0.1% saponin in a moist staining chamber for 1 hr.
Hoescht stain (20 ng/ml final) was added with the secondary
antibody where indicated. Finally, DC were washed two times
with PBS and one time with milliQ H20, and then mounted using
Fluoromount G (Southern Biotech, Birmingham, AL).
IFN-c detection by ELISPOT
Antigen specific activation of T cells was detected by measuring
interferon-c (IFN-c) production by ELISPOT. 96-well nitrocellu-
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coated as recommended by the manufacturer with 10 mg/ml
capture mouse anti-IFN-c in 0.1 M NAHCO3 pH 9.6 (1-D1K;
Mabtech, Nacka, Sweden) overnight at room temperature. Plates
were then washed 3615 min. with PBS, and blocked with RPMI/
10% human serum for 1 h at room temperature. Day 5 DC (1–
2610
4/well) were loaded with the indicated concentration of
CFP10 peptide or protein antigen for 1 hr at 37uC, 5% CO2.
CD4
+ clonal T cells specific for CFP10 were then added (2610
4/
well), and the plate was incubated overnight at 37uC, 5% CO2.
Addition of 100 mM Ht31 or Ht31p (Promega, Madison, WI) or





Cambridge, Ontario, Canada)) occurs 20 minutes before addition
of antigen. After washing six times with PBS/0.05% Tween 20
(Sigma), 100 mlo f1 mg/ml biotinylated secondary anti-IFN-c
mAb (7B6-1; Mabtech) in 0.5%FBS in PBS was added and
incubated for 2 h at room temperature. Plates were then washed
again 66with PBS/0.05% Tween 20, 100 ml avidin/biotinylated
enzyme (HRP) complex (Vectastain ABC Elite Kit; Vector,
Burlingame, CA) was added to wells, and the plates were
incubated for 1 h. Plates were again washed 66with PBS/0.05%
Tween 20, then 100 ml of 3-amino-9-ethylcarbazole substrate
(Vectastain AEC substrate kit; Vector) was added. After 4–10 min,
the colorimetric reaction was stopped by washing thoroughly with
distilled water, and plates were air-dried. Spots were quantitated
using an AID ELISPOT High Resolution Reader System (Cell
Technology, Inc, Columbia, MD).
Mixed Lymphocyte Reaction
Ten thousand DC matured from CD14
+ monocytes (Easy Sep)
with GM-CSF and IL-4 (see above) were plated in 96 well
nitrocellulose-backed plates with 125,000 or 62,500 PBMC for
three days at 37uC, 5% CO2. IFN-c was detected by ELISPOT as
described above.
ELISA
In a 96 well plate, 15–30,000 adherence isolated day 5 DC were
incubated with 10 ng/ml LPS without or with 100 mM Ht31 or
Ht31p for 16–18 hrs. Supernatants were collected and 100 ml was
used in an IL-10 ELISA (R&D Systems) as per manufacturer
protocol. For TNF-a ELISA, CD14
+ monocytes were isolated by
negative selection (as described above) and incubated for 5 days
with GM-CSF and IL-4 (both 10 ng/ml). These day 5 DC were
plated in a 96 well plate at 5,000/well and incubated without or
with LPS (10 ng/ml) and without or with Ht31 (100 mM) or
Ht31p (100 mM) and PGE2 (1 mM), where indicated, for 24 hrs at
37uC, 5% CO2. Supernatants were used in a TNF-a ELISA as per
manufacturers protocol (Ebioscience).
ANNEXIN V/PI STAINING
Adherence isolated day 5 DC were collected, plated at 200,000
per well in a 96 well ULA plate and incubated without or with
100 mM Ht31 or Ht31p for 18 hours at 37uC, 5% CO2. Cells
were collected, rinsed with PBS and stained with annexin V and
propidium iodide (PI) per manufacturers protocol (BD Pharmin-
gen).
FACS
Adherence isolated day 5 DC were collected, plated at 100,000
per well in a 96 well ULA plate and incubated without or with
10 ng/ml LPS or 1 mM PGE2, without or with 100 mM Ht31 or
Ht31p for 48 hrs at 37uC, 5% CO2. Cells were collected rinsed
with PBS, blocked with FACS buffer (2% human serum, 2% goat
serum, 0.5% fetal bovine serum in PBS) for 30 minutes at room
temperature and stained with conjugated antibody for 45 minutes
at 4uC, FITC-conjugated anti-CD18, PE-conjugated anti-CD49,
FITC-conjugated anti-CD11a, PE-conjugated anti-CD11b, PE-
conjugated anti-CCR7, APC-conjugated anti-CD11c (Ebio-
science) and FITC-conjugated anti-CD80, PE-conjugated anti-
CD40, PE-conjugated anti-CD83, APC-conjugated anti-CD86,
FITC-conjugated anti-HLA-DR (BDbiosciences). Acquisition was
performed with an LSRII flow cytometer using FACS Diva
software. All analyses were performed using FlowJo software
(TreeStar).
Supporting Information
Figure S1 Day 5 DC were incubated without or with 10 ng/ml
LPS and 100 mM Ht31 or Ht31p for 48 hours. Cells were
collected, blocked, and stained for cell surface expression using
conjugated antibodies, see materials and methods. FACS analysis
was performed on a LSRII using FacsDiva software. A, E upper
panels) One representative histogram showing untreated cells
(black trace), Ht31 treated cells (red trace), and Ht31p treated cells
(blue trace). B) Graphical representation of percent inhibition of
mean fluorescent intensities compared to untreated samples, data
from eight donors was normalized and averaged. C, E lower
panels) One representative histogram showing untreated cells
(black trace), LPS treated cells (orange trace), LPS+Ht31 (red
trace), and LPS+Ht31p (blue trace). D) Graphical representation
of percent increase in mean fluorescent intensity compared to
untreated cells, data from five donors was normalized and
averaged. F) Graphical representation of average mean fluorescent
intensity (MFI), data from at least three donors was normalized
and averaged.
Found at: doi:10.1371/journal.pone.0004807.s001 (1.01 MB TIF)
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